(Q21195820)

17 August 2022

D Skowasch

2

D

Skowasch

1 reference

17 August 2022

S Pabst

3

S

Pabst

1 reference

17 August 2022

E Jansen

4

E

Jansen

1 reference

17 August 2022

I Tuleta

5

I

Tuleta

1 reference

17 August 2022

C Grohé

6

C

Grohé

1 reference

European Journal of Medical Research

17 August 2022

language of work or name

English

0 references

publication date

12 September 2011

0 references

published in

0 references

volume

16

0 references

issue

9

0 references

page(s)

407-10

0 references

cites work

The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3352146

The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma

12 September 2017

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3352146

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

30 May 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3352146

30 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F2047-783X-16-9-407

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2047-783X-16-9-407

The IgE repertoire in PBMCs of atopic patients is characterized by individual rearrangements without variable region of the heavy immunoglobulin chain bias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2047-783X-16-9-407

Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2047-783X-16-9-407

Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2047-783X-16-9-407

Failure of omalizumab for treatment of severe adult atopic dermatitis

21 January 2018

1 reference

12 December 2020

Treatment of recalcitrant atopic dermatitis with omalizumab

1 reference

12 December 2020

Efficacy of anti-IgE therapy in patients with atopic dermatitis

1 reference

12 December 2020

Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels

1 reference

12 December 2020

Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis

1 reference

12 December 2020

10.1186/2047-783X-16-9-407

Identifiers

DOI

1 reference

release_6b6qxuan3ze6bguvxfd322nwzm

0 references

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6b6qxuan3ze6bguvxfd322nwzm

24 November 2022

mapped directly with Wikidata item

1 reference

1 reference

PubMed publication ID

22024441

1 reference